Literature DB >> 8639531

Cellular and in vitro transport of glutathione conjugates by MRP.

H Shen1, S Paul, L M Breuninger, P J Ciaccio, N M Laing, M Helt, K D Tew, G D Kruh.   

Abstract

MRP is a recently identified ATP-binding cassette transporter. We previously established that MRP confers resistance to a spectrum of natural product cytotoxic drugs [Kruh, G.D., (1994) Cancer Res. 54, 1649-1652], that expression of MRP is associated with enhanced drug efflux [Breuninger, L.M., (1995) Cancer Res. 55, 5342-5347], and that MRP transcript is widely expressed in human tissues and solid tumor cell lines [Kruh, G.D., (1995) J. Natl. Cancer Inst. 87, 1256-1258]. In the present study the relationship between MRP and drug glutathione S-conjugates was examined. We observed that MRP was labeled by azidophenacylglutathione (APA-SG), a photoaffinity analog of glutathione, and that inside-out membrane vesicles prepared from MRP-overexpressing HL60/ADR cells transported this compound. Transport into membrane vesicles was ATP-dependent, sensitive to osmolarity, and saturable with regard to APA-SG and ATP concentrations, with Km values of 15 and 61 microM, respectively. APA-SG transport was competitively inhibited by the natural product cytotoxic drugs daunorubicin, vincristine, and etoposide, with Ki values of 4.8, 3.8, and 5.5 microM, respectively. Oxidized glutathione, the drug-glutathione S-conjugate DNP-SG, the LTD4 antagonist MK571 and arsenate were also competitive inhibitors, with Ki values of 9.0, 23.4, 1.1, and 15.0 microM, respectively. Analysis of the fate of monochlorobimane in MRP transfectants revealed reduced intracellular concentrations of drug-glutathione S-conjugates associated with enhanced efflux and altered intracellular distribution. These results indicate that MRP can transport glutathione conjugates in vitro and in living cells and suggest the possibility that the transporter may represent a link between cellular resistance to some classes of cytotoxic drugs and glutathione-mediated mechanisms of resistance. In addition, the observation that both mildly cationic or neutral natural product cytotoxic drugs and anionic compounds such as DNP-SG, MK571, and arsenate are competitive inhibitors of MRP action suggests that the substrate specificity of the transporter is quite broad.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8639531     DOI: 10.1021/bi960098n

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  9 in total

1.  ATP-dependent uptake of natural product cytotoxic drugs by membrane vesicles establishes MRP as a broad specificity transporter.

Authors:  S Paul; L M Breuninger; K D Tew; H Shen; G D Kruh
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

2.  The extended-MDR phenotype.

Authors:  R Davey; M Davey
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

3.  Inhibition of the MRP1-mediated transport of the menadione-glutathione conjugate (thiodione) in HeLa cells as studied by SECM.

Authors:  Dipankar Koley; Allen J Bard
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-07       Impact factor: 11.205

4.  The human multidrug-resistance-associated protein MRP1 mediates ATP-dependent transport of unconjugated bilirubin.

Authors:  Igino Rigato; Lorella Pascolo; Cristina Fernetti; J Donald Ostrow; Claudio Tiribelli
Journal:  Biochem J       Date:  2004-10-15       Impact factor: 3.857

5.  Development and characterization of a recombinant Madin-Darby canine kidney cell line that expresses rat multidrug resistance-associated protein 1 (rMRP1).

Authors:  Ziping Yang; Micha Horn; Joanne Wang; Danny D Shen; Rodney J Y Ho
Journal:  AAPS PharmSci       Date:  2004-03-09

6.  Cysteinyl leukotrienes are autocrine and paracrine regulators of fibrocyte function.

Authors:  Kevin M Vannella; Tracy R McMillan; Ryan P Charbeneau; Carol A Wilke; Peedikayil E Thomas; Galen B Toews; Marc Peters-Golden; Bethany B Moore
Journal:  J Immunol       Date:  2007-12-01       Impact factor: 5.422

7.  Multidrug resistance-associated transporter 2 regulates mucosal inflammation by facilitating the synthesis of hepoxilin A3.

Authors:  Michael Pazos; Dario Siccardi; Karen L Mumy; Jeffrey D Bien; Steve Louie; Hai Ning Shi; Karsten Gronert; Randall J Mrsny; Beth A McCormick
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

8.  Cytotoxicity of rhein, the active metabolite of sennoside laxatives, is reduced by multidrug resistance-associated protein 1.

Authors:  B A P van Gorkom; H Timmer-Bosscha; S de Jong; D M van der Kolk; J H Kleibeuker; E G E de Vries
Journal:  Br J Cancer       Date:  2002-05-06       Impact factor: 7.640

9.  In vivo cisplatin resistance depending upon canalicular multispecific organic anion transporter (cMOAT).

Authors:  T Minamino; M Tamai; Y Itoh; Y Tatsumi; M Nomura; K Yokogawa; H Suzuki; Y Sugiyama; T Ohshima; K Miyamoto
Journal:  Jpn J Cancer Res       Date:  1999-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.